A few years ago, contrary to the recommendations in Pharmaplasia and in the face of an industry-wide “patent cliff” and a rapidly changing healthcare market, the Pharma industry went on a binge of mega-mergers and multi-billion dollar acquisitions. The book Pharmaplasia had identified large organizational size as not only challenging but as a liability in the evolving new healthcare market. But “Big Pharma” wanted to get “Bigger” and it took years for Pharma to appreciate the need for change that had been recommended in Pharmaplasia; “eliminate facilities, people, and support systems that no longer have a role in the evolving new healthcare market.” Now, more recently, we have seen unprecedented downsizings, including elimination of facilities and people in massive restructurings at some Big Pharma.
Sure, change can take time, especially in large public corporations. The status quo and doing “what we have always done” is easier but it merely delays the inevitable and can give current frontline employees a false sense of accomplishment and security.
There are over 20 specific recommendations for change in Pharmaplasia that could accelerate a positive evolution for Pharma. If these recommendations are being ignored by your company for now, it may be just a matter of time before you are affected?
With the information and recommendations in Pharmaplasia you can determine how the changing Pharma business model will affect you in this evolving new healthcare market. Better yet, Pharmaplasia can help you determine how to align yourself with these changes so you can participate in these positive changes and not be caught off guard by the inevitable. mike@pharmareform.com
